<DOC>
	<DOCNO>NCT03030937</DOCNO>
	<brief_summary>The purpose study determine whether apatinib plus irinotecan improve progression free survival compare single irinotecan patient advance gastric cancer adenocarcinoma esophagogastric junction fail one line chemotherapy .</brief_summary>
	<brief_title>Clinical Trial Compare Apatinib Plus Irinotecan Versus Single Irinotecan Second-line Treatment AGC EGJA</brief_title>
	<detailed_description>Gastric cancer lead cause cancer death China . Most patient unresectable metastatic disease time diagnosis , prognosis poor.Systemic therapy require patient advanced stage . Platinum combine fluoropyrimidines always consider first line treatment . After failure initial therapy , single agent irinotecan use second line treatment , limited survival benefit.Apatinib , novel target inhibitor VEGF receptor 2 ( VEGFR2 ) .The purpose study determine whether apatinib plus irinotecan improve progression free survival compare single irinotecan patient advance gastric cancer adenocarcinoma esophagogastric junction fail one line chemotherapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Age：18~70years ; 2 . Subjects Histologically cytologically confirm advanced gastric cancer adenocarcinoma esophagogastric junction ； 3 . Subjects must receive one line treatment participating , receive irinotecan antiangiogenic（including apatinib）treatment previously ; Note： ( 1 ) Time firstline treatment subject advance tumour must 1 cycle ; ( 2 ) Adjuvant / neoadjuvant therapy allow ; adjuvant / neoadjuvant therapy consider firstline treatment disease recurrence treatment le 24 week . 4. subject least one measurable lesion define RECIST ( version 1.1 ) ; Lesions previously treat radiotherapy locoregional therapy must show radiographic evidence disease progression deem target lesion . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1； 6 . Survival expectation≥ 3 month ; 7 . The interval subject receive cytotoxic drug , radiotherapy surgery must 4 week ( besides nitroso mitomycin must 6 week ) , wind healed participating ; 8 . No serious concomitant disease ( include heart , lung , liver jaundice gastrointestinal obstruction ) ; 9 . Adequate organ function define indicated below： （1）Adequate bone marrow function , define : ( blood transfusion within 14 day ) 1 . Hemoglobin ( Hb ) ≥80g/L， 2 . White blood count ( WBC ) ≥3.5×109/L 3 . Absolute neutrophil count ( ANC ) ≥1.5×109/L， 4 . Platelet count ( PLT ) ≥75×109/L； （2）Adequate liver function , define : 1 . Bilirubin ≤1.5×the upper limit normal ( ULN ) 2 . Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) ≤3.0× ( ULN ) , Glutamyl transpeptidase ( GGT ) ≤2.5× ( ULN ) , ( When liver metastasis , ALT AST GPT &lt; 5.0× ( ULN ) ) . 3. serum creatinine ≤1.0×（ULN） , creatinine clearance &gt; 50 mL/min ( calculate per Cockcroft Gault formula ) 10 . Females childbearing potential must pregnancy test 7 day participate ( include serum urine ) , result negative , Females childbearing potential must agree use highly effective method contraception throughout entire study period 8 week study drug discontinuation . Male subject must successful vasectomy female partner must meet criterion ( i.e.not childbearing potential practicing highly effective contraception throughout study period 8 week study drug discontinuation ) . 11 . Subjects provide write informed consent participating , Willing able comply aspect protocol 1 . Females lactate pregnant Screening Baseline 2 . Subjects active malignancy ( except definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) 3 . Subjects symptomatic brain metastases； 4 . Subjects uncontrolled blood pressure medication ( 140/90 mmHg ) , 5 . Subjects coronary heart disease ( CHD ) grade I , arrhythmia ( include Prolongation QTc interval : Male subject &gt; 450 m , Females &gt; 470 m ) cardiac dysfunction ; . 6 . Subjects gastrointestinal bleeding tendency , include follow : current local active ulcerative lesion fstool OB ( + + ) ; history melena hematemesis within past 2 month ; current fstool OB ( + ) gastric primary tumor without surgical , investigator considerd ulcerative stomach cancer associate risk gastrointestinal bleeding . 7 . Subjects bleed tendency ，defined abnormal coagulation ( INR &gt; 1.5× ( ULN ) , APTT &gt; 1.5 × ( ULN ) ) ; 8 . Subjects previous history cardiovascular cerebrovascular disease , receive thrombolytic anticoagulant exclude 9 . Subjects urine protein positive ( defined urine protein detection 2+ , urine protein ≥ 1 g/24 hour ) ; 10 . Subjects variety factor affect oral medication ( inability swallow , persistent nausea vomiting , chronic diarrhea intestinal obstruction , . ) ; 11 . Subject condition opinion investigator would preclude his/her participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>